Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Times New Jersey.
Press releases published on July 7, 2025
From Investment to Real Estate: U.S. Accepts Bitcoin for Home Purchases, and LET Mining Helps Asset Growth
GlobeNewswire
·
July 7, 2025
New York City, NY, July 07, 2025 (GLOBE NEWSWIRE) -- As new federal guidelines enable cryptocurrency to qualify as a mortgage asset, U.S. homeowners can now leverage Bitcoin directly in home purchases—with LET Mining poised to support this evolution by …
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
GlobeNewswire
·
July 7, 2025
ART12.11, the Patented CBD:TMP Cocrystal, Demonstrates Potent Antidepressant-Like Activity and Cognitive Benefits Over Leading SSRI Data Being Presented at the 35th Annual International Cannabinoid Research Society Symposium SOLANA BEACH, Calif., July 07, …
Medicines for Poland Announces: Without pharmaceutical factories Europe will lose any war
GlobeNewswire
·
July 7, 2025
BRUSSELS, July 07, 2025 (GLOBE NEWSWIRE) -- The need to establish a fund under the EU budget to support the production of critical medicines in Europe is a conclusion drawn from an analysis of the impact of the war on the availability of medicines in …
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
GlobeNewswire
·
July 7, 2025
8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks Results from the 240mg Q8W …
Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)
GlobeNewswire
·
July 7, 2025
LOUISVILLE, Ky., July 07, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol Myers Squibb to its comprehensive list of limited distribution therapies. Augtyro …
CryptoMiningFirm 2025 Trusted Free Bitcoin Cloud Mining Platform Launches New Mobile App
GlobeNewswire
·
July 7, 2025
San Francisco, California, July 07, 2025 (GLOBE NEWSWIRE) -- In the cryptocurrency space, few platforms have as high a revenue stream as CryptoMiningFirm - and CryptoMiningFirm is one of them. It provides a worry-free, secure, and environmentally friendly …
Bluewave Nexor: This Bluewave Nexor App Sets New Standard in AI-Driven Trading with Unmatched Security and User Approval
GlobeNewswire
·
July 7, 2025
New York City, NY, July 07, 2025 (GLOBE NEWSWIRE) -- As digital transformation continues to redefine global markets, Bluewave Nexor has emerged as one of the most talked-about innovations in AI-driven trading. At a time when market unpredictability and …
BTC Miner Announces Million-Dollar Cloud Mining Opportunity After Bitcoin’s Surge
GlobeNewswire
·
July 7, 2025
New York City, NY, July 07, 2025 (GLOBE NEWSWIRE) -- You may have missed the Bitcoin surge, but the opportunity isn’t over. BTC Miner offers you a low-barrier, high-reward investment opportunity where you can easily participate in Bitcoin, Ethereum, and …
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
GlobeNewswire
·
July 7, 2025
-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new …
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
GlobeNewswire
·
July 7, 2025
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from …
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
GlobeNewswire
·
July 7, 2025
Completion of enrollment achieved nearly one year ahead of schedule Primary analysis anticipated two years post-treatment TOKYO and LONDON and BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, today announced the last …
Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema
GlobeNewswire
·
July 7, 2025
Ingelheim, Germany, July 7, 2025 – Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study (NCT06962839). It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision …
OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025
GlobeNewswire
·
July 7, 2025
Oxford, United Kingdom – 7th July 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that …
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
GlobeNewswire
·
July 7, 2025
WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Shoals Technologies Group, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call
GlobeNewswire
·
July 7, 2025
PORTLAND, Tenn., July 07, 2025 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (the “Company”) (Nasdaq: SHLS) today announced that the Company will release its second quarter 2025 results before market open on Tuesday, August 5, 2025, to be followed by …
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
GlobeNewswire
·
July 7, 2025
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that …
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
GlobeNewswire
·
July 7, 2025
WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer …
Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
GlobeNewswire
·
July 7, 2025
Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX-801 confers durable protection after a single dose TNX-801 is well tolerated in immunocompromised animals, without evidence of …
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
GlobeNewswire
·
July 7, 2025
Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development …
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
GlobeNewswire
·
July 7, 2025
In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions. Biomarker …